The Pandemic Effect Chinese Covid-19 Vaccines Remains Crucial for Developing Nations: Global Data

Editor: Ahlam Rais

As the world struggles to fight the pandemic, the demand and supply gaps for Covid-19 vaccines is widening. In this background, Global Data reveals that Chinese vaccines remain crucial for developing nations.

Related Companies

Among the top 15 economies, Brazil and Mexico are the only two countries that have approved Chinese vaccines.
Among the top 15 economies, Brazil and Mexico are the only two countries that have approved Chinese vaccines.
(Source: ©shintartanya - stock.adobe.com)

London/UK – Beijing-based pharmaceutical company Sinovac Biotech’s Coronavac vaccine was recently found to be 49.6 % effective in real-world data from Brazil. However, considering the global demand for Covid-19 vaccines and the supply-demand gaps, Chinese vaccines remain crucial for developing nations’ vaccination programs irrespective of real-world data, says Global Data, a leading data analytics and research company.

China has so far provided Covid-19 vaccine aid to more than 50 developing nations and Sinovac Biotech alone has already supplied over 150 million doses to other countries. However, Chinese Covid-19 vaccines were always criticized for lack of peer-reviewed data over efficacy in Phase III trials.

Prashant Khadayate, Pharma Analyst at Global Data, comments: “Real-world data is crucial for understanding vaccine effectiveness. All nations require highly effective vaccines, like those from Pfizer/Biontech and Moderna, which have shown high efficacy rates even in real-world usage.

“Chinese vaccines, on the other hand, have shown varied efficacy rates across countries in clinical trial settings from just over 50 % to 79 %. Real-world data serves to validate the data observed in a clinical trial setting. However, low efficacy observed in real-world data will not hurt the future uptake as developed nations have already stockpiled large quantities of Covid-19 vaccines from leading manufactures like Pfizer, Moderna, Astra Zeneca, and Johnson & Johnson, leading to inadequate supply for developing nations.”

China’s Pharmaceutical Equipment Market - Current Status, Trends and Recommendations for Action

As China is emerging as one of the world’s fastest-growing markets for the consumption of pharmaceuticals, it also offers huge opportunities for the global equipment industry.

This 40-page report aims to help you gain a better understanding of the current China's pharmaceutical market regarding a series of pharmaceutical industry related policies. Based on results of the survey among users in the pharmaceutical industry and the expert interviews, it will also provide you with a forecast for the industry and recommendations for your future operating and investment in China.

According to Global Data’s ‘Coronavirus Disease (Covid-19) Pharma Executive Briefing – April 20, 2021’, among the top 15 economies, Brazil and Mexico are the only two countries that have approved Chinese vaccines.

It is important to note that most of the Covid-19 vaccines being supplied to developing countries are by companies based out of Russia, China, and India. However, India is currently struggling with a severe second wave of Covid-19 and the focus is shifting towards vaccinating its own population and less towards supplying to other nations.

As a result, the WHO-backed Covax initiative has slashed the number of vaccines to be delivered by the end of May from about 240 million doses to 145 million doses. Moreover, the Covax initiative was only able to supply 41 million doses so far of its two billion doses promised by the end of 2021.

Khadayate concludes: “Chinese vaccine manufacturers are already playing a key role in supplying vaccines to developing countries. The supply of Covid-19 vaccines from China are expected to improve further and be of increased importance amid the supply issues within India in the wake of the second wave of Covid-19.”

(ID:47368265)